陕西省延安地区女性HPV感染及基因分型年龄分布

目的 宫颈癌的发生发展与人乳头瘤病毒(human papillomavirus,HPV)密切相关,本研究分析陕西省延安地区女性宫颈HPV感染情况及基因亚型年龄分布,为本地区女性宫颈癌防治和HPV感染的分子流行病学研究提供重要依据.方法 选择2011-01-01-2015-07-31延安大学附属医院体检(478例)、"两癌"筛查、机会性筛查(2 250例)及就诊(814例)的3 542例女性患者作为研究对象,采用PCR体外扩增和DNA反向点杂交相结合的DNA芯片技术进行HPV基因分型检测.结果 HPV感染率为40.54%(1 436/3 542),其中高危型HPV感染率38.42%(1 361/3 542);低危型HPV感染率3.78%(134/3 542);感染年龄分布以≥61岁年龄组感染率最高,其次是51~60岁年龄组.各年龄组HPV感染率和高危感染率比较差异均有统计学意义,P<0.05;低危感染率比较差异无统计学意义,P>0.05.按年龄组统计,高危亚型检出频次由高到低排列前3位,≤30岁年龄组为HPV16、HPV58和HPV39,其余各组均为HPV16、HPV58和HPV52.低危感染以HPV6和HPV11为主.单一型别感染占总感染人数的74.72%(1 073/1 436),其中单一高危感染占69.56%(999/1 436),单一低危占5.15%(74/1 436).多重感染占总感染人数的25.27%(363/1 436),最高检出四重感染.单一感染率、单一高危感染率最高的为41~50岁年龄组,多重高危感染率和高低危混合多重感染率最高的是≥61岁年龄组,各年龄组高低危混合多重感染率比较差异有统计学意义(P<0.05),其余感染类型差异均无统计学意义,P>0.05.结论 陕西省延安地区HPV感染年龄分布以≥61岁年龄组较高,主要亚型为HPV16、HPV58和HPV52,感染类型以单一感染为主,提示HPV亚型的分析对疫苗的研发和宫颈癌的筛查及防治有指导意义.     

陕西省宝鸡地区妇女人群HPV-DNA亚型分析

目的:探讨陕西省宝鸡地区妇女人群人乳头瘤病毒(HPV)感染亚型分布特征.方法:采用聚合酶链反应(PCR)反向点杂交技术对HPV进行分型检测.结果:宝鸡地区妇女人群HPV总感染率为35.92%,高危、低危、高低危感染率分别为24.27%、9.21%和2.44%.单一、高危单一和高危多重感染率分别为28.54%20.51%和3.76%.在20岁以下和60岁以上年龄段均有较高感染率.高危型感染率在大于60岁年龄段最高.单一感染常见亚型为16、6、58、11、53、52型;多重感染常见亚型为16、11、6、58、51、53型;总体感染常见亚型为16、6、58、11、53、52型;分别占本组感染71.58%、60.47%和66.86%.不同年龄段妇女人群常见亚型,≤20岁为58、6、39、11、16、56型,21~30岁为6、16、11、52、58、39型,31~40岁为16、6、58、11、52、53型,41~50岁为16、6、58、11、52、51型,51~60岁为16、6、53、11、58、42型,>60岁为16、6、58、11、53、56型;分别占本组感染76.86%、74.12%、71.33%、65.65%、60.92%和73.57%.在多重感染中以二重感染最为多见(5.67%),占多重感染的76.89%.单一、多重和总体HPV16亚型分别占24.34%、13.06%和20.04%.结论:陕西省宝鸡地区妇女人群HPV感染率较高,其常见高危亚型为16、58、53、52、39、56型,低危型为6和11型.不同年龄段亚型分布各有不同.总体、高危、低危和高低危感染率在不同年龄段均有显著差异.     

广西南宁地区妇女子宫颈HPV感染型别的分析

目的 分析广西南宁地区妇女子宫颈HPV感染类型,研究其分布的规律.方法 采用基因芯片法对1250名门诊机会性筛查的妇女按自愿原则采用HPV基因分型检测.结果 HPV-DNA检测阳性者占31.36%( 392/1250).HPV-DNA亚型以低危型感染为主,感染率由高到低排列为6、11、43型;高危亚型感染率由高到低排列为16、58、52、18.HPV高危亚型以单一型别感染为主,其次为单一低危亚型感染.在多重感染中以低危和高危型别的二重混合感染为主;而三重、四重感染少见.感染者年龄≤25岁者占42.35%,其次为25～34岁.结论 HPV感染亚型分布有一定的区域性,该检测可用于宫颈癌的筛查,以确定感染型别,有利于预测病变转归,指导临床治疗和随访.     

延安、榆林两市女性宫颈HPV感染基因型别的对比研究

目的:对陕西省陕北地区的延安市和榆林市妇女人群人乳头状瘤病毒(human papillomavirus,HPV)感染及亚型分布特征进行对比研究.方法:采用PCR-反向斑点杂交技术对来自延安市3 459例和来自榆林市的2 256例宫颈脱落细胞标本进行HPV基因分型检测.结果:延安市妇女人群总感染率为40.76%(1 410/3 459),高危感染率为38.65%(1 337/3 459),低危感染率为3.85%(133/3 459);陕西省榆林市总感染率为30.36%(685/2 256),高危感染率为29.03%(655/2 256),低危感染率为3.06%(69/2 256);延安市HPV感染率、高危感染率均高于榆林市(P<0.05),低危感染率无统计学差异(P>0.05).两地的感染率的年龄分布一致,均为≥61岁年龄段最高,其次是51~60岁、≤30岁和31~40岁,41~50岁最低.高危感染延安市≥61岁年龄段也为最高,其次从高到低依次是51~60岁、31~40岁、41~50岁、≤30岁;榆林市51~60岁年龄段为最高,其次从高到低依次是≤30岁、≥61岁、31~40岁、41~50岁.低危感染延安市和榆林市分布基本一致,从高到底依次是≥61岁、≤30岁、31~40岁、51~60岁、41~50岁.延安市各年龄段的感染率、高危感染率和低危感染率均高于榆林市(P<0.05),低危感染除≤30岁年龄组有统计学意义(P<0.05)外,其余各年龄段比较无统计学意义(P>0.05).延安市高危感染中以16型最高,其次是58、52、18、53、39;榆林市也以HPV16感染最为常见,其次为52、58、53、51、18型.低危感染中两地均以6型最高,其次是11型和43型.两地妇女人群单一感染均最为常见,其次为二重感染,延安市的单一感染率、二重感染率均高于榆林市,且二者差异具有统计学意义(P<0.05).延安市的单一低危感染率、单一高危感染率、二重高危感染率、三重及三重以上高危感染率、三重及三重以上混合感染率均高于榆林市(P<0.05).榆林市二重混合感染率高于延安市(P<0.05).结论:延安市和榆林市妇女HPV感染状况各有其特点,研究各地HPV感染状况对宫颈癌的防治具有重要意义.     

广元及周边地区宫颈疾病妇女人乳头状瘤病毒感染现状分析

目的分析广元地区宫颈疾病妇女人乳头状瘤病毒（HPV）感染的现状。方法选取2012年10月11日至2013年6月17日间门诊及住院就诊的1260名患宫颈疾病患者。采集患者的宫颈脱落细胞标本,应用导流杂交基因分型技术（HybriMax）对其进行HPV检测和基因分型。分析广元地区宫颈疾病感染HPV的概率、高危型HPV（HR-HPV）的感染率,以及比邻地区HPV亚型的分布现状。结果宫颈疾病HPV感染率为36.6%,重叠感染率为13.4%,高危型（HR-HPV）感染率为47.5%,低危型（LR-HPV）感染率为27.9%,HR-HPV感染率高于LR-HPV感染率。排在前5位的感染型为HPV-58、52、16、53、33;人群HPV年龄段总感染率在≤24岁组出现高峰,而后又在35～39岁组出现高峰,45～49岁组出现低谷,≥60岁出现升高,≥60岁组HPV感染率最高。宫颈炎症患者感染HPV类型谱以高危型HPV-16、58及低危型HPV 11为主,宫颈不典型增生患者感染HPV类型谱以高危型HPV-16、52、58为主,宫颈癌患者HPV类型谱以高危型HPV-16为主。结论广元地地宫颈疾病妇女人乳头状瘤病毒（HPV）感染现状为高感染率和高重叠感染率,HPV的亚型不同,且不同地区HPV亚型的分布也不同。     

广东江门地区30889例妇科门诊妇女HPV感染型别分析

目的:研究广东省江门地区人乳头瘤病毒(HPV)感染率、基因分型和年龄分布特征,确定本地区的优势型别及高风险人群,为该地区HPV 流行病学的研究提供理论依据.方法:采用凯普医用核酸分子快速杂交仪,对30 889名2009年3月-2015年8月到江门市中心医院妇科门诊就诊的女性进行生殖道21种HPV感染基因亚型筛查.结果:江门地区妇女HPV感染率为24.69%(7 625/30 889),高危型HPV感染率为21.32%(6 584/30 889),低危型HPV感染率为3.37%(1 041/30 889),感染率最高基因型是HPV16型,其次为52、58、18、53和CP8304型.不同年龄妇女高危型HPV阳性率比较差异有统计学意义(P<0.05),>60岁妇女阳性率最高.结论:江门地区妇女HPV感染率高,且以高危型单一基因亚型感染为主;感染基因型别主要以HPV-16、52、58、18、53和CP8304为主,具有一定的地域差异性;52及58型感染率高,对于疫苗的研制和开发有参考意义.     

广西南宁地区妇女子宫颈HPV感染型别的分析

目的分析广西南宁地区妇女子宫颈HPV感染类型,研究其分布的规律。方法采用基因芯片法对1250名门诊机会性筛查的妇女按自愿原则采用HPV基因分型检测。结果HPv．DNA检测阳性者占31．36％（392／1250）。HPV-DNA亚型以低危型感染为主,感染率由高到低排列为6、11、43型;高危亚型感染率由高到低排列为16、58、52、18。HPV高危亚型以单一型别感染为主,其次为单一低危亚型感染。在多重感染中以低危和高危型别的二重混合感染为主;而三重、四重感染少见。感染者年龄≤25岁者占42．35％,其次为25～34岁。结论HPV感染亚型分布有一定的区域性,该检测可用于宫颈癌的筛查,以确定感染型别,有利于预测病变转归,指导临床治疗和随访。     

HPV分型研究在宫颈癌筛查中的意义

目的:探讨HPV分型流行病学特征及其与宫颈癌前病变的关系。方法:选择陕西省人民医院2014年1月-2014年12月在妇科门诊就诊、有性生活史并行宫颈液基细胞学（TCT）检查的患者10 885例,其中2 677例患者同时行宫颈感染人乳头瘤病毒（HPV）分型筛查。结果:TCT异常率（≥ASCUS）7.6%; HPV感染率 34.8%,其中高危型HPV占76.93%,低危型HPV占23.93%;混合感染（2种以上HPV亚型感染）占20.28%,高危型HPV感染主要型别为HPV16、HPV52、HPV58;低危型HPV感染主要型别为HPV6、HPV11、HPV43;未发现HPV26、73、83型阳性病例;≤29岁及≥50岁年龄段为HPV感染及TCT异常的高峰年龄段;HPV 感染率随着细胞学诊断级别及病理学诊断级别的升高而显著上升。结论:不同年龄段HPV 分型感染率及 TCT 异常率不同,HPV 感染率与宫颈病变严重程度呈显著正相关。     

中国女性人乳头瘤病毒感染状况及高危型别分布的Meta分析

目的分析人乳头瘤病毒(human papillomavirus,HPV)在我国不同地区妇女中的感染情况及高危型别分布,以期为制定有效的地区宫颈癌防治策略及HPV疫苗的研制提供科学的基础数据。方法通过检索查询文献,综合分析并评价2011年7月前在国内发表的有关HPV在宫颈组织中感染及高危型别分布的相关研究。结果 HPV在我国普通女性中的感染率为15.71%,低于宫颈病变患者(15.71%vs82.43%,P0.05)。北方地区高危型HPV的平均感染率高于南方(41.57%vs14.81%,P0.05),少数民族自治区高危型HPV的平均感染率高于其他省市(56.36%vs 17.11%,P0.05)。全国范围内前6位常见高危型HPV分布依次为:HPV-16、HPV-52、HPV-58、HPV-33、HPV-18、HPV-31型。HPV-16型是我国最为常见的感染型别,其他型别在不同地区及人群中的分布有一定差异。结论 HPV的感染率及高危型别分布在我国不同地区及不同人群中有一定差异,HPV-16、HPV-52和HPV-58型是中国特有的优势感染型别。     

陕西省榆林地区妇女人群HPV感染亚型分布研究

目的:对陕西省榆林地区妇女人群人乳头状瘤病毒(human papillomavirus,HPV)感染及亚型分布特征进行研究。方法:采用PCR-反向斑点杂交技术对735例宫颈脱落细胞标本进行HPV基因分型检测。结果:735例妇女人群中共检出HPV阳性者220例,总感染阳性率为29.93%(220/735),其中高危型感染阳性率为25.85%（190/735,包括多重高危感染）,低危感染阳性率为2.31%（17/735）;高低危混合感染阳性率为1.77%(13/735)。在被检测的16个高危HPV亚型中,最常见类型依次为16、58、53、52、18和51型,未检测出45型;在被检测的3种低危HPV亚型中依次为6、11、43型。HPV阳性者中单一基因型感染率23.67%（174/735）,占HPV感染79.09%(174/220);单一高危型感染率为21.36%（157/735）,占HPV感染71.36%(157/220),占单一感染90.23%（157/174）。多重感染率为6.26%（46/735）,占HPV感染20.91%（46/220）;在多重感染中以二重感染最为常见达4.35%（32/735）,占HPV总感染14.55%(32/220)。不同年龄段妇女人群HPV感染率分别为29.41%、31.92%、31.33%、28.40%、32.65%和41.66%,各组数据无统计学差异（P>0.05）。结论:陕西省榆林地区妇女人群宫颈HPV感染率较高,在单一感染中以16、52、58、33、51和11比较常见;在多重感染中以16、58、53、52、18和51型比较常见,综合统计则以16、52、58、53、51和18型感染比较常见。各年龄段妇女人群均有较高的感染率。     

MGMT prognostic impact on glioblastoma is dependent on therapeutic modalities

MGMT promoter methylation, which has been correlated with the response to alkylating agents, was investigated in a retrospective series of 219 glioblastomas (GBMs) treated with various modalities. MGMT methylation had no impact on survival for the whole group, but showed a significant advantage (17.1 months vs. 13.1) for patients treated with RT+ adjuvant chemotherapy (relative risk of death (RR) = 0.53; P = 0.041), particularly when patients received CT during the course of RT (MS = 19.9 months vs. 12.5 months; RR = 0.227, P = 0.001). This suggests that the prognostic impact of MGMT methylation is dependent on therapeutic modalities and schedules. MGMT methylation was not correlated with the main molecular alterations, such as 10q loss and p53 expression.     

Effects of amifostine on perfused isolated rat heart and on acute doxorubicin-induced cardiotoxicity

Purpose: To determine the effects of amifostine on an isolated perfused rat-heart model and its protective activity with regard to cardiotoxic doxorubicin perfusion. Methods: Langendorff constant-pressure isolated rat-heart preparations were used to analyze the effects of the drugs during a 40-min period of perfusion after a 20-min stabilization interval. The first study was conducted with amifostine alone (controls and 10⁻⁶, 10⁻⁵, and 10⁻⁴ M amifostine; n=6 in each group). The second study was conducted with amifostine and doxorubicin (controls, 2.5 × 10⁻⁵ M doxorubicin, 2.5 × 10⁻⁵ M doxorubicin and 10⁻⁵ M amifostine, and 2.5 × 10⁻⁵ M doxorubicin and 10⁻⁴ M amifostine; n=4 in each group). Results: Amifostine had no significant effect on hemodynamic parameters at 10⁻⁶, 10⁻⁵, and 10⁻⁴ M concentrations. However, amifostine increased the coronary flow expressed as a percentage ± SEM of the baseline flow as follows: 82 ± 4% for controls, 95 ± 6% for 10⁻⁶ M amifostine, (P=0.13), 111 ± 4% for 10⁻⁵ M amifostine (P < 0.01), and 104 ± 3% for 10⁻⁶ M amifostine (P < 0.01). When we commenced an amifostine perfusion 20 min in advance of and then during a 40-min perfusion with doxorubicin, at a cardiotoxic concentration of 2.5 × 10⁻⁵ M the left ventricular pressures (LVDP, expressed as percentages ± SEM of the baseline LVDP before doxorubicin) were 55 ± 3% for the doxorubicin controls, 68 ± 2% for doxorubicin with 10⁻⁵ M amifostine (P=0.05), and 80 ± 3% for doxorubicin with 10⁻⁴ M amifostine (P < 0.01). Whether this protective effect might be related to the known free-radical-scavenging activity of amifostine remains to be determined. Conclusion: On a Langendorff-type model of rat heart, 10⁻⁵ and 10⁻⁴ M amifostine alone induced a coronary dilation and, when associated with a cardiotoxic concentration of 2.5 × 10⁻⁵ M doxorubicin, 10⁻⁵ and 10⁻⁴ M amifostine displayed a cardioprotective effect. Received: 9 March 1998 / Accepted: 6 July 1998     

Update on CML-Like Disorders

Chronic myeloid leukemia (CML) is defined for many years as BCR-ABL1 positive disease, but older publications refer to a poor prognosis, clinically heterogeneous entity termed ‘BCR-ABL1 negative CML’ constituting about 5% of CML cases. Apart from very rare CML cases with cytogenetically cryptic, atypical variant BCR-ABL1 fusions that had been inadvertently missed during the diagnostic work up, most of these cases would now be classified as a subtype of myelodysplastic/myeloproliferative neoplasm (MDS/MPN), such as atypical CML (aCML), chronic myelomonocytic leukemia (CMML), or chronic neutrophilic leukemia (CNL). A minority would be classified as systemic mastocytosis with associated hematological neoplasm (SM-AHN), myeloid/lymphoid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, FGFR1 or with PCM1-JAK2 (MLN-eo), or chronic eosinophilic leukemia not otherwise specified (CEL-NOS).¹     

'Weighing in' on screening mammography

Background Obesity is associated with increased post-menopausal breast cancer risk. Overweight and obese women also tend to have a poorer prognosis when diagnosed with breast cancer compared with their matched normal weight peers. In previous studies obesity was associated with decreased utilization of screening mammography. We present a study examining the association between Body Mass Index (BMI) and compliance with recommended mammographic screening using data from the 2004 Behavioral Risk Factor Surveillance Survey (BRFSS). Patients and methods We included 130,185 female participants, aged 40 and older, who were randomly selected to participate in the world largest telephone survey. After weighted analysis, this is representative of 56,226,220 non-institutionalized US women. The primary outcome was the proportion of women who underwent screening mammography within the last 2 years preceding the survey stratified by BMI. The mammography screening behavior of normal weight women (BMI 18.5–24.99) was compared with underweight (<18.5), overweight (25–29.99), and women with obesity class I (30–34.99), class II (35–39.99), and class III (≥40) using logistic regression analysis and weighted to provide estimates of women in the United States (US). Results Our sample included 1.91% underweight, 37.91% normal weight, 30.15% overweight and 14.36%, 5.44%, and 3.49% women with obesity classes’ I–III respectively. Approximately 7% of women age 40 and older had insufficient information to calculate their BMI. Adjusting for age, race, smoking status, general health perception, level of education, and income level, underweight women had lower odds of complying with regular screening mammography (OR 0.57; 95% CI, 0.48–0.68). Women with obesity class III (OR 0.97; 95% CI, 0.84–1.13) showed a trend towards underutilization of screening mammograms which was not clinically significant. In contrary, in overweight women a significantly higher association with appropriate mammography utilization was identified OR 1.08 (95% CI, 1.01–1.15). Although not statistically significant, women with class I and II obesity showed a trend towards a higher utilization 1.08 (95% CI, 0.99–1.18) and 1.10 (95% CI, 0.98–1.25) respectively, when compared to women at desired weight. Conclusion We present a weighted analysis of the BRFSS, evaluating the association of BMI and appropriate screening mammography among women 40 years and older. These results are generalizable to the US population of women in this age range. Underweight women had significantly lower odds of utilizing screening mammography appropriately when compared with women at desired weight. Results from previous studies reporting underutilization of screening mammography in high risk, obese, and overweighed women were not confirmed in this largest population based analysis performed to date.     

Histopathological study on the effects of hyperthermia on microvasculature

Recent experimental evidence suggests that hyperthermia has profound effects on tumor tissue microcirculation. Indeed, this is one of the suggested mechanisms involved in the anti-tumor effects of heat. Groups of WAG-Rij rat transplanted tumors (rbabdomyosarcoma-BA1112) were ireated with local hyperthermia (Radio-Frequency). Various temperatures (ranging from 38° to 43°C) were used. Animals were subsequently sacrificed at 1, 3, and 24 hours after beating and tumors were subjected to detailed pathological studies for evaluation of the effects of heat on microcireulation as well as on tumor cells. The results are indicative of no specific changes in microvasculature up to 40.5°C. At intermediate temperatures (42°C) vessels show marked dilatation and congestion (?stasis). At higher temperatures (44.5°C) there is massive hemorrhage and necrosis with rupture of vessel walls. The degree and intensity of this process also depends on the interval between heating and time of sacrifice of the animal. Detailed results are presented. The correlation of pathological findings and blood flow observations as well as their relevance to treatment of cancer patients are discussed.     

Spotlight on Geminin

In the previous issue of Breast Cancer Research, Gardner and co-workers describe a novel interaction between Geminin, a protein that prevents reinitiation of DNA replication, and Topoisomerase IIα (TopoIIα), an enzyme essential for removing catenated intertwines between sister chromatids. Geminin facilitates the action of TopoIIα, thereby promoting termination of DNA replication at the same time it inhibits initiation. In this manner, Geminin ensures that cells duplicate their genome once, but only once, each time they divide. Remarkably, either depletion of Geminin or over-expression of Geminin inhibits the action of TopoIIα, thereby making Geminin an excellent target for cancer chemotherapy.     

Effect of antacid on imatinib absorption

Purpose  Imatinib often causes gastric upset resulting in frequent co-administration of an antacid. Elevated gastric pH, delayed gastric emptying, or introduction of Mg²⁺/Al³⁺ could potentially change imatinib absorption, thereby affecting the therapeutic effectiveness of imatinib. Indeed, antacid co-administration with dasatinib does result in a twofold decrease in dasatinib absorption. We aimed to define the effect of antacid on the pharmacokinetics of imatinib. Methods  Twelve healthy subjects were enrolled in a 2-period, open-label, randomized cross-over, fixed-sequence study. In one period, each subject received 400 mg imatinib p.o., and in the other, the same dose of imatinib preceded by 20 mL antacid, containing 1.6 g Al(OH)₃ + 1.6 g Mg(OH)₂, 15 min before imatinib. Plasma concentrations of imatinib and its active N-desmethyl metabolite CGP74588 were determined by LC–MS, and data were analyzed non-compartmentally. Results  Antacid administration did not significantly affect the area under the plasma imatinib concentration versus time curve (AUC) [31.7 μg/(mL h) alone versus 32.6 μg/(mL h) with antacid, P = 0.37; 80% power]. Conclusions  Our results indicate that the use of Mg²⁺-Al³⁺-based antacid does not significantly affect imatinib absorption. WinNonlin software was provided as part of the Pharsight Academic Licensing Program.     

基于CiteSpace的我国癌症筛查中文文献可视化分析CSCD

目的分析1990—2018年间中国癌症筛查中文文献的知识结构、主要研究力量、发展趋势及研究热点。方法以中国知网、万方、维普数据库中1990—2018年间发表的癌症筛查领域中文文献为研究资料,使用CiteSpace5.2.R2对其进行共现分析、聚类分析、突现词分析。结果中国癌症筛查领域所发表的中文文献呈逐年递增的发展态势,核心作者群的学术引领作用尚未发挥,主要学术群体可分为3类;基本知识框架以妇科恶性肿瘤筛查为核心,中国癌症筛查中文文献存在9大研究方向;研究前沿集中在筛查种类向其他国内高发癌种扩散、筛查方法的更新、对癌症筛查相关交叉学科的重视等方面。结论中国癌症筛查领域所发表的中文文献已取得一定成绩,主要集中在医学技术及其相关领域,对癌症筛查方法的循证医学评价、卫生经济学评价以及卫生政策方面的研究较少。     

Study on apoptosis-inducing effect of XIAP antisense oligonucleotides on glioblastoma cells in vitro

OBJECTIVE To investigate the apoptosis-inducing effect of XIAP antisense oligonucleotides on glioblastoma cells in vitro.
METHODS There were 4 groups in our experiment. Group A, as a cell control group, had normal cell culture and no treatment applied. Group B, as a blank control group, had normal cell culture and no liposome control of ASODN. Group C was N-ODN. Group D was the ASODN group. RT-PCR and Western blot assay were conducted to detect the expression of XIAP in all A-172 ceil groups after treatment with XIAP antisense oligonucleotides （ASODN）. MTT assay and flow-cytometry （FCM） detection were used to detect the ability of cell anchoring growth and apoptotic rates of all groups. The processing time was 72 h.
RESULTS The expression of XIAP in the A-172 cells was greatly down-regulated, after treated with XIAP-ASODN. Among different concentrations of ASODN, the 300nM was the most optimal one. The down-regulation of XIAP obviously inhibited the succinate dehydrogenase （SDH） activity of the A-172 cells and the increased apoptotic rate of A-172 cells （87.45%） was significantly higher than that of the A-172 in the control groups. There was a statistically significant difference between the treatment and control groups （P 〈 0.01）.
CONCLUSION The XIAP-ASODN can effectively regulate the expression of the XIAP down, as a result, inhibit the growth of the glioblastoma cells （A-172） and obviously increase the apoptotic rate of the A-172 cells. The results killing role of XIAP-ASODN to the of the study manifest an overt glioblastoma cells.     

CD47与淋巴瘤免疫治疗相关性的研究进展

CD47属于免疫球蛋白超家族成员,在人体多种细胞和组织上均有表达,但在肿瘤细胞上表达得更多,特别是在各种造血系统肿瘤中高表达。肿瘤细胞上表达的CD47与巨噬细胞上的信号调节蛋白α（SIRPα）结合抑制巨噬细胞对肿瘤的吞噬作用可导致肿瘤免疫逃逸。近年来CD47成为肿瘤研究的新热点,本文就CD47的结构与表达、CD47-SIRPα、靶向CD47抗体药物与淋巴瘤免疫治疗相关性研究作一综述。